Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)

Posted

National Institutes of Health

Description

This notice of funding opportunity (NOFO) provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be supported. Therapeutic agents include small molecules, biologics or biotechnology-derived products. The goal of this NOFO is to spur therapeutic development for a variety of rare diseases by advancing projects to the point where they would attract subsequent investment supporting full Investigational New Drug (IND) application development or progression to clinical trials in the case of repurposing or repositioning.

Who can apply

  • State governments
  • County governments
  • City or township governments
  • Special district governments
  • Independent school districts
  • Public and State controlled institutions of higher education
  • Native American tribal governments (Federally recognized)
  • Public housing authorities / Indian housing authorities
  • Native American tribal organizations (other than Federally recognized)
  • Nonprofits with 501(c)(3) status (other than higher education)
  • Nonprofits without 501(c)(3) status (other than higher education)
  • Private institutions of higher education
  • For-profit organizations other than small businesses
  • Small businesses
  • Others

Contact

NIH Grants Information <br/>grantsinfo@nih.gov
grantsinfo@nih.gov

Key dates & funding
  • PostedDec 6, 2024
  • ClosesJul 2, 2027
  • CFDA93.350
Categories

Pro insight

Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.

Unlock with Pro